Our USP is Portability, Ease of operation, Rapid (<30 min results) and Affordability (< $5 or Rs.300).
Just a drop of blood and we can identify the stage of cancer, the possibility of cancer onset and patient treatment monitoring. The portable device is easy to operate in any remote location.
Initial prototype “L-Sens” for a point-of-care liver cancer diagnosis is already ready that was supported by BIRAC-Bio Ignition Grant Our multianalyte on-chip sensing platform with mobile interface for easy data display, transfer, and storage. We can achieve the target of large scale clinical performance evaluation and launch the product within 24-36 months and also extend product for other deep tissue cancers.
We also will include an artificial intelligence engine in our toolkit to predict the onset of cancer. The toolkit uses blood samples and biomarker profiles of these samples to detect the potential risk of cancer. We have collected extensive biomarkers samples of patients and healthy individuals to train 16 different machine-learning models to learn and detect the risk of cancer. The toolkit will have these models as an in-built AI-engine, which could analyze the biomarker immediately, and suggest preventive actions if it predicts the onset of cancer.
The global market on in-vitro diagnosis devices (IVD) has a huge market size and expected to reach $94 Billion in 2025. While in India, the estimated size is more than $700. Million in 2018 and would expect to reach $1.5-1.7 billion markets by 2020 at a 5-year CAGR 15 – 20%. The main customers for the IVD markets are the stand-alone and chain of Laboratories, Government/ private hospitals, Physicians, pathologists, CROs (as the diagnosis is integral for clinical trials) and Lab heads/Pathologists and NGOs.